Total reported value
$563.6M
Reporting period: 2026-03-31 · Number of holdings: 29
Patient Square Capital LP disclosed 29 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $563.6M and a quarterly turnover rate of 51.2%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "P"
Trim INSM
-41.0% -$20.7M
Add ROIV
0.0% $49.0M
Add COGT
+87.8% $11.7M
Trim ABVX
-6.7% -$4.0M
Trim MIRM
-23.0% -$2.3M
Trim EYPT
+1.9% -$4.0M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 40.13% | +2.20% | — | |
| 2 | ARGX | Argenx Se - Adr | Stock-Healthcare | 4.76% | +0.08% | +41.22% | |
| 3 | INSM | Insmed INC | Stock-Healthcare | 4.57% | -5.38% | -41.01% | |
| 4 | ONC | Beone Medicines Ltd-adr | Stock-Other | 4.24% | -0.27% | +16.20% | |
| 5 | COGT | Cogent Biosciences INC | Stock-Other | 4.07% | +1.66% | +87.79% | |
| 6 | MIRM | Mirum Pharmaceuticals INC | Stock-Other | 3.77% | -1.28% | -23.00% | |
| 7 | BLTE | Belite Bio INC - Adr | Stock-Other | 3.30% | +3.30% | NEW | |
| 8 | LEGN | Legend Biotech Corp-adr | Stock-Other | 3.18% | +3.18% | NEW | |
| 9 | NKTR | Nektar Therapeutics | Stock-Other | 2.68% | +2.68% | NEW | |
| 10 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 2.57% | +1.10% | +93.16% | |
| 11 | PHVS | Pharvaris N.V. | Stock-Other | 2.47% | -0.75% | -9.16% | |
| 12 | ABVX | Abivax Sa-adr | Stock-Other | 2.40% | -1.35% | -6.73% | |
| 13 | XENE | Xenon Pharmaceuticals INC | Stock-Other | 2.34% | +1.03% | +66.30% | |
| 14 | CELC | Celcuity INC | Stock-Other | 1.92% | -0.64% | -20.83% | |
| 15 | EYPT | Eyepoint INC | Stock-Other | 1.82% | -1.23% | +1.92% | |
| 16 | MRK | Merck & Co. INC. | Stock-Healthcare | 1.71% | +1.71% | NEW | |
| 17 | ARQT | Arcutis Biotherapeutics INC | Stock-Other | 1.67% | +0.36% | +90.78% | |
| 18 | ALLO | Allogene Therapeutics INC | Stock-Other | 1.49% | +0.03% | -30.50% | |
| 19 | KYMR | Kymera Therapeutics INC | Stock-Other | 1.48% | -0.84% | -28.06% | |
| 20 | DNTH | Dianthus Therapeutics INC | Stock-Other | 1.40% | +0.08% | -37.41% | |
| 21 | ELVN | Enliven Therapeutics INC | Stock-Other | 1.39% | +0.37% | -35.09% | |
| 22 | CATX | Perspective Therapeutics INC | Stock-Other | 1.20% | +0.53% | +43.45% | |
| 23 | DFTX | Definium Therapeutics INC | Stock-Other | 1.11% | +1.11% | NEW | |
| 24 | HROW | Harrow INC | Stock-Other | 1.03% | +0.96% | +2249.72% | |
| 25 | TARA | Protara Therapeutic INC | Stock-Other | 0.95% | +0.95% | NEW | |
| 26 | CTMX | Cytomx Therapeutics INC | Stock-Other | 0.91% | +0.91% | NEW | |
| 27 | RCUS | Arcus Biosciences INC | Stock-Other | 0.75% | -0.12% | +14.71% | |
| 28 | ASMB | Assembly Biosciences INC | Stock-Other | 0.67% | -0.25% | +7.33% | |
| 29 | SYRE | Spyre Therapeutics INC | Stock-Other | 0.01% | -1.04% | -99.33% |
Performance for Q3 2026
+14.6%
Performance Last 4 Quarters
+134.3%
Based on 88% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 29 | $563.6M | 51 | |
| 2025-12-31 | 28 | $467.1M | 43 | |
| 2025-09-30 | 24 | $373.9M | 61 | |
| 2025-06-30 | 19 | $277.4M | 0 | |
| 2025-03-31 | 19 | $241.7M | 0 | |
| 2024-12-31 | 20 | $267.4M | 0 | |
| 2024-09-30 | 11 | $269.4M | 0 | |
| 2024-06-30 | 2 | $215.4M | 0 | |
| 2024-03-31 | 2 | $234.8M | 0 | |
| 2023-12-31 | 2 | $182.9M | 0 | 1ROIV2270087 |
| 2023-09-30 | 2 | $182.0M | 0 | 1ROIV2270087 |
| 2023-06-30 | 2 | $205.4M | 0 | 1ROIV2270087 |
| 2023-03-31 | 2 | $124.4M | 0 | 12700872ROIV |
| 2022-12-31 | 2 | $236.5B | 0 | 12700872ROIV |
Patient Square Capital LP's most significant position changes for 2026-03-31: New buy: Belite Bio INC - Adr (BLTE); New buy: Legend Biotech Corp-adr (LEGN); New buy: Nektar Therapeutics (NKTR); Sold out: Terns Pharmaceuticals INC (430); New buy: Merck & Co. INC. (MRK).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ROIV | Roivant Sciences Ltd. | +2.2% | — | Unchanged |
| 2 | COGT | Cogent Biosciences INC | +1.7% | +87.79% | Add |
| 3 | DBVT | Dbv Technologies Sa-spon Adr | +1.1% | +93.16% | Add |
| 4 | XENE | Xenon Pharmaceuticals INC | +1% | +66.30% | Add |
| 5 | HROW | Harrow INC | +1% | +2249.72% | Add |
| 6 | CATX | Perspective Therapeutics INC | +0.5% | +43.45% | Add |
| 7 | ELVN | Enliven Therapeutics INC | +0.4% | -35.09% | Trim |
| 8 | ARQT | Arcutis Biotherapeutics INC | +0.4% | +90.78% | Add |
| 9 | ARGX | Argenx Se - Adr | +0.1% | +41.22% | Add |
| 10 | DNTH | Dianthus Therapeutics INC | +0.1% | -37.41% | Trim |
| 11 | ALLO | Allogene Therapeutics INC | 0% | -30.50% | Trim |
| 12 | RCUS | Arcus Biosciences INC | -0.1% | +14.71% | Add |
| 13 | ASMB | Assembly Biosciences INC | -0.3% | +7.33% | Add |
| 14 | ONC | Beone Medicines Ltd-adr | -0.3% | +16.20% | Add |
| 15 | CELC | Celcuity INC | -0.6% | -20.83% | Trim |
| 16 | PHVS | Pharvaris N.V. | -0.8% | -9.16% | Trim |
| 17 | KYMR | Kymera Therapeutics INC | -0.8% | -28.06% | Trim |
| 18 | SYRE | Spyre Therapeutics INC | -1% | -99.33% | Trim |
| 19 | EYPT | Eyepoint INC | -1.2% | +1.92% | Add |
| 20 | MIRM | Mirum Pharmaceuticals INC | -1.3% | -23.00% | Trim |
| 21 | ABVX | Abivax Sa-adr | -1.4% | -6.73% | Trim |
| 22 | INSM | Insmed INC | -5.4% | -41.01% | Trim |
| 23 | BLTE | Belite Bio INC - Adr | — | NEW | New buy |
| 24 | LEGN | Legend Biotech Corp-adr | — | NEW | New buy |
| 25 | NKTR | Nektar Therapeutics | — | NEW | New buy |
| 26 | 430 | Terns Pharmaceuticals INC | — | EXIT | Sold out |
| 27 | MRK | Merck & Co. INC. | — | NEW | New buy |
| 28 | LQDA | Liquidia CORP | — | EXIT | Sold out |
| 29 | DFTX | Definium Therapeutics INC | — | NEW | New buy |
| 30 | OCUL | Ocular Therapeutix INC | — | EXIT | Sold out |
| 31 | IRON | Disc Medicine INC | — | EXIT | Sold out |
| 32 | AVTX | Avalo Therapeutics INC | — | EXIT | Sold out |
| 33 | TARA | Protara Therapeutic INC | — | NEW | New buy |
| 34 | CTMX | Cytomx Therapeutics INC | — | NEW | New buy |
| 35 | AMLX | Amylyx Pharmaceuticals INC | — | EXIT | Sold out |
Institutions with a similar AUM
CIK 0001688511
Total reported value
$563.5M
16 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001802516
Total reported value
$563.9M
13 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0002001943
Total reported value
$563.2M
168 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001263508
Total reported value
$17.4B
84 stks
2026-03-31
2 of the top 5 holdings overlap, including Beone Medicines Ltd-adr
CIK 0001493215
Total reported value
$10.0B
88 stks
2026-03-31
2 of the top 5 holdings overlap, including Insmed INC
CIK 0001839209
Total reported value
$3.8B
6 stks
2026-03-31
2 of the top 5 holdings overlap, including Insmed INC